Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

UTHR

+ Watchlist+ Portfolio

United Therapeutics Corp.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$577.34
52-Week Range
$455.63 – $614.23
Market Cap
$23.81B
P/E (TTM)
21.11
EPS (TTM)
26.49
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.78
PEG Ratio
2.22
Return on Equity
19.13%
Return on Assets
10.91%
Gross Margin
86.34%
Operating Margin
39.38%
Profit Margin
38.61%
Current Ratio
4.61
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$454.62M
Revenue Growth
4.10%
Earnings Growth
-20.30%
Enterprise Value
$22.52B

Market Snapshot

About

United Therapeutics Corp. is a biotechnology company focused on the development and commercialization of innovative therapies for patients with chronic and life-threatening conditions. The company specializes in treatments for pulmonary arterial hypertension and has expanded into organ transplantation technologies and other therapeutic areas. United Therapeutics is known for its work in rare diseases and has multiple approved products generating significant revenue.